Can one company disrupt the entire lab industry? 23andMe seems determined to find out. The Mountain View, California-based personal genomics and biotechnology company, which first marketed its … [Read more...]
TESTING TRENDS
Genetics Update: 23andMe Seeks to Upend the Medical Industry via Genetic Testing Information Sharing
August 27, 2019
TESTING STRATEGY
Upfront Next-Generation Sequencing for Lung Cancer Patients Saves Time, Money
August 5, 2019
Use of upfront next-generation sequencing (NGS) testing at diagnosis of patients with metastatic non-small-cell lung cancer (mNSCLC) is associated with substantial cost savings, according to a study … [Read more...]
GENETIC TESTING
Guidelines at a Glance
July 22, 2019
Screening for HIV Published June 11 in the Journal of the American Medical Association. The U.S. Preventive Services Task Force (USPSTF) recommends screening for HIV infection in adolescents and … [Read more...]
TESTING STRATEGY
Preventive Genomic Screening In Young Adults Highly Cost Effective
March 26, 2019
A new model shows that universal preventive genomic screening for multiple conditions in early adulthood could be highly cost-effective in a single-payer health care system, according to a study … [Read more...]
EMERGING TESTS
Study Showing PGx Testing Improves Depression Outcomes, Key to Myriad’s Reimbursement Strategy
February 18, 2019
Pharmacogenomic testing (PGx) provides clinically meaningful improvement in response and remission rates for difficult-to-treat depression patients over standard of care, according to a study … [Read more...]
THE BUSINESS OF TESTING
Payer Medical Policies Can Promote Effective Use of Comprehensive Sequencing In Community Oncology Setting
January 22, 2019
Comprehensive genomic profiling (CGP) identifies clinically relevant genomic alterations that can be used to inform treatment decisions in community-based oncology practices that benefit both patients … [Read more...]
TESTING TRENDS
Zika Blood Screening Not Cost-Effective, Study Finds
January 22, 2019
Screening blood donors for Zika virus is not cost-effective in the United States or Puerto Rico, according to a study published Jan. 8 in the Annals of Internal Medicine. Despite U.S. Food and Drug … [Read more...]
